Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study

INTRODUCTION: Small molecule inhibitors of the terminal step in intrahepatic triglyceride synthesis (diacylglycerol acyltransferase 2 inhibitor (DGAT2i, PF-06865571, ervogastat)) and upstream blockade of de novo lipogenesis via acetyl-coenzyme A carboxylase inhibitor (ACCi, PF-05221304, clesacostat)...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Neeta B, Darekar, Amanda, Anstee, Quentin M, Wong, Vincent Wai-Sun, Tacke, Frank, Vourvahis, Manoli, Lee, Douglas S, Charlton, Michael, Alkhouri, Naim, Nakajima, Atsushi, Yunis, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968568/
https://www.ncbi.nlm.nih.gov/pubmed/35354614
http://dx.doi.org/10.1136/bmjopen-2021-056159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968568/
https://www.ncbi.nlm.nih.gov/pubmed/35354614
http://dx.doi.org/10.1136/bmjopen-2021-056159

Ejemplares similares